Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Archer Aviation Inc (ACHR) vs Moderna, Inc. (MRNA) Price & Performance

Archer Aviation IncTrade
Moderna, Inc.Trade

Price performance (Past 24H)

Key statistics

Archer Aviation Inc vs Moderna, Inc. — how do they compare? Archer Aviation Inc trades at $6.3 (market cap $5.23B), while Moderna, Inc. trades at $60.51 (market cap $24.18B). The key difference: Moderna, Inc. is far larger — about 4.6× Archer Aviation Inc's market cap, and Moderna, Inc. is trading nearer its 52-week high, Archer Aviation Inc nearer its low. Which is the better fit depends on your goals.

ACHRMRNA
Market Cap
$5.23B$24.18B
Sector
IndustrialsHealth
52-Week High
$13.64$81.80
52-Week Low
$4.44$22.36
Enterprise Value
$3.79B$20.33B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Archer Aviation Inc

Archer Aviation (ACHR) trades at $6.30, up 0.64% today, with a bullish technical outlook from moving averages but overbought RSI signals. The company reported a Q2 2026 revenue beat but sustained heavy losses, with a net income margin of -11,589.86% in 2026. Recent news highlights a strategic deal with Boeing to acquire three businesses, broadening its defense and AI aviation portfolio, which fueled a significant stock rally.

The outlook remains speculative with high execution risks amid substantial cash burn, but analyst sentiment is strongly bullish (77.78% buy ratings) due to regulatory progress and Boeing's backing. Key risks include dilution from equity offerings, certification delays, and profitability challenges in the nascent eVTOL market.

Moderna, Inc.

Moderna (MRNA) trades at $63.70, up 6.5% recently, with a bullish technical signal and strong moving average support. Despite negative net income margins, the company beat Q2 2026 EPS estimates and secured FDA approval for its mRNA flu vaccine, mFLUSIVA, signaling diversification beyond COVID-19. Revenue has declined from pandemic peaks but is projected to stabilize around $2.2B in 2026.

The outlook is mixed: near-term catalysts from new vaccine approvals and pipeline progress offer upside, but persistent losses and high valuation multiples pose risks. Analyst consensus is cautious with a hold-heavy rating, reflecting uncertainty over profitability timelines amid ongoing R&D investments.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Archer Aviation Inc

Archer Aviation develops electric vertical takeoff and landing (eVTOL) aircraft for urban air mobility. Its flagship, Midnight aircraft, is designed for air taxi services, aiming to transform urban travel with sustainable aviation.

Read more on ACHR

About Moderna, Inc.

Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.

Read more on MRNA